Cancer Clinical Trials | Research Pipeline Overview | US & International
Clinical Trial Intelligence
A curated index of oncology clinical trials, refreshed daily from public registry data, organized to support discovery, landscape understanding, and research planning.
How experimental oncology research is studied, reported, and evaluated across Phase I–IV trials
Educational overview of oncology clinical trials referenced in public research registries, including studies of mRNA vaccines, CAR-T cell therapies, immunotherapy, and other investigational approaches to support understanding.
Clinical trials play a central role in the evolution of oncology evidence. They are research studies that test new treatments, procedures, or devices to determine their safety and effectiveness.
Clinical Trial Intelligence is designed to improve visibility into research activity, therapeutic development, emerging interventions, and changing areas of scientific focus across cancer research ecosystems. Rather than focusing on individual studies in isolation, Clinical Trial Intelligence seeks to provide structured context around how oncology research evolves across diseases, therapies, biomarkers, and scientific priorities.
This page provides an educational overview of oncology clinical trials referenced in public research registries, including studies of mRNA vaccines, CAR-T cell therapies, immunotherapy, and other investigational approaches to support understanding.
Important Notice:
This page provides an educational overview of oncology clinical research as reported in public registries. It does not provide medical advice, trial recruitment, enrollment assistance, referrals, or care navigation.
Eligibility, participation, and treatment decisions must be determined by qualified healthcare professionals and trial investigators.
Framework
Core Clinical Trial Intelligence Areas
Four structured lenses for understanding how oncology research evolves across diseases, therapies, and priorities.
Trial Activity
Explore patterns in oncology clinical trial activity across cancer types, therapeutic categories, and evolving research priorities.
Therapeutic Development
Examine areas of emerging treatment investigation, novel interventions, and changing therapeutic approaches.
Research Momentum
Monitor areas of accelerating clinical research activity and shifting scientific focus.
Emerging Opportunities
Identify developing areas of oncology investigation, unmet needs, and future directions of clinical research.
Research Inquiry
Questions Clinical Trial Intelligence Can Help Explore
Where is clinical trial activity accelerating?
Which cancers are attracting increasing research attention?
Which therapies are entering clinical investigation?
Where are evidence gaps driving new trials?
Which biomarkers are associated with emerging trial activity?
How are oncology research priorities evolving over time?
Important Research Context Notice
This page provides an educational overview of oncology clinical research as reported in public registries. It does not provide medical advice, trial recruitment, enrollment assistance, referrals, or care navigation.
Eligibility, participation, and treatment decisions must be determined by qualified healthcare professionals and trial investigators.
Status reflects most recent public registry update and may not reflect real-time enrollment or protocol changes.
Trials shown are ClinicalTrials.gov records included in the CS index. Coverage reflects the countries and studies currently ingested and is not a complete list of oncology trials. Open the linked registry record for current study details.
Trial records are refreshed automatically from the ClinicalTrials.gov registry via scheduled daily retrieval.
1000 U.S. Clinical Trials on Page 1
Referenced in public trial registries • 1000 records per page
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I/II, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fanconi Anemia in Affected Fetuses
Trial ID: NCT07408583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Trial ID: NCT07053020
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 25, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial ID: NCT07594548
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 18, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Trial ID: NCT07812246
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration
Trial ID: NCT06907485
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration
Trial ID: NCT06907485
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration
Trial ID: NCT06907485
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration
Trial ID: NCT06907485
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Trial ID: NCT07729046
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Trial ID: NCT07577999
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 23, 2026
Conditions (Registry-Reported):
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Trial ID: NCT07437963
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Trial ID: NCT07437963
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Trial ID: NCT07437963
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Trial ID: NCT07437963
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
Trial ID: NCT06800092
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
A Phase I/II Study of Metronomic Temozolomide With Dexbrompheniramine for Patients With Recurrent High-Grade Glioma/Glioblastoma
Trial ID: NCT07859059
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot Study
Trial ID: NCT04861077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 17, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
Trial ID: NCT07229339
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: February 5, 2026
Conditions (Registry-Reported):
Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
Trial ID: NCT07619521
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Trial ID: NCT07389278
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial ID: NCT07551596
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 6, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Trial ID: NCT06948084
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)
Trial ID: NCT07516366
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
Trial ID: NCT07621614
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care
Trial ID: NCT07650656
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 22, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Trial ID: NCT07842965
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
Trial ID: NCT07863765
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Trial ID: NCT07875413
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Trial ID: NCT07875413
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
Trial ID: NCT07605416
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 24, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of ASTX727 With Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy
Trial ID: NCT07437950
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07758673
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 11, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma
Trial ID: NCT07463807
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 13, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial ID: NCT07582172
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial ID: NCT07582172
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial ID: NCT07582172
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial ID: NCT07582172
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS
Trial ID: NCT07582172
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Trial ID: NCT07349693
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 10, 2026
Conditions (Registry-Reported):
Non-Opioid Postoperative Pain Management in Skin Cancer Surgery: A Randomized Trial of Suzetrigine Versus Standard Analgesia in Minnesota
Trial ID: NCT07843134
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 25, 2026
Conditions (Registry-Reported):
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
Trial ID: NCT05676489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia
Trial ID: NCT04266275
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 8, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial ID: NCT07332507
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
Trial ID: NCT07578116
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
Trial ID: NCT07578116
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy
Trial ID: NCT07578116
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 9, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Trial ID: NCT07388524
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])
Trial ID: NCT07856719
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Trial ID: NCT07850973
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
Trial ID: NCT07029776
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 2, 2026
Conditions (Registry-Reported):
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Trial ID: NCT07843550
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Trial ID: NCT07843537
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma
Trial ID: NCT06708455
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: March 19, 2026
Conditions (Registry-Reported):
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Trial ID: NCT07832266
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 21, 2026
Conditions (Registry-Reported):
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Trial ID: NCT07703436
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
A Phase 0 Clinical Trial of Oral Gallium Maltolate for Recurrent Glioblastoma
Trial ID: NCT07515924
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Trial ID: NCT07137481
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 20, 2026
Conditions (Registry-Reported):
Merging Strategy That Uses Gut Microbiome Profiling and Targeted Modulation to Improve CAR-T Cell Therapy Outcomes, Predict Responses, and Reduce Toxicity
Trial ID: NCT07871747
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Merging Strategy That Uses Gut Microbiome Profiling and Targeted Modulation to Improve CAR-T Cell Therapy Outcomes, Predict Responses, and Reduce Toxicity
Trial ID: NCT07871747
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Merging Strategy That Uses Gut Microbiome Profiling and Targeted Modulation to Improve CAR-T Cell Therapy Outcomes, Predict Responses, and Reduce Toxicity
Trial ID: NCT07871747
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Teclistamab in Relapsed or Refractory Waldenstrom's Macroglobulinemia
Trial ID: NCT07791498
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 1, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Trial ID: NCT07791264
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Unresectable, Recurrent, or Metastatic Gastrointestinal Stromal Tumors
Trial ID: NCT07647068
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Trial ID: NCT07156227
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Trial ID: NCT07783594
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes
Trial ID: NCT07281547
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 5, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Trial ID: NCT07743138
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 18, 2026
Conditions (Registry-Reported):
A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
Trial ID: NCT07346196
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: January 20, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial ID: NCT07748611
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 6, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Losartan in Combination With Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Trial ID: NCT07265739
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 22, 2026
Conditions (Registry-Reported):
Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Trial ID: NCT07781891
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 24, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial
Trial ID: NCT07470489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial
Trial ID: NCT07470489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial
Trial ID: NCT07470489
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial ID: NCT07140315
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Trial ID: NCT07178912
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Trial ID: NCT07178912
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Trial ID: NCT07178912
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Trial ID: NCT07178912
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Trial ID: NCT07753824
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 27, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
Piloting a Novel Therapeutic for Sleep Disturbance in Palliative Care Over 5 Weeks: The PILLOW Study
Trial ID: NCT07658677
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
Piloting a Novel Therapeutic for Sleep Disturbance in Palliative Care Over 5 Weeks: The PILLOW Study
Trial ID: NCT07658677
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Home-Based Outpatient Model for BCG Delivery: Reducing Undue Burden of NMIBC Treatment (Home-Run) Trial
Trial ID: NCT07874347
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Piloting a Novel Therapeutic for Sleep Disturbance in Palliative Care Over 5 Weeks: The PILLOW Study
Trial ID: NCT07658677
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation
Trial ID: NCT03833206
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: April 20, 2026
Conditions (Registry-Reported):
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Trial ID: NCT07729397
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 27, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors
Trial ID: NCT07847957
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Trial ID: NCT07069699
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Trial ID: NCT07069699
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Trial ID: NCT07069699
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
Trial ID: NCT07069699
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer
Trial ID: NCT07864584
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 8, 2026
Conditions (Registry-Reported):
A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer
Trial ID: NCT07864584
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 8, 2026
Conditions (Registry-Reported):
A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer
Trial ID: NCT07864584
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 8, 2026
Conditions (Registry-Reported):
A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer
Trial ID: NCT07864584
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 8, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Trial ID: NCT07714551
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Trial ID: NCT07691450
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 9, 2026
Conditions (Registry-Reported):
Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Trial ID: NCT07153055
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery
Trial ID: NCT07587749
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Trial ID: NCT07153055
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery
Trial ID: NCT07587749
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myeloid Malignancies
Trial ID: NCT05565105
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Trial ID: NCT07153055
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery
Trial ID: NCT07587749
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
An Open-Label, Phase II Study Evaluating the Feasibility, Safety, and Efficacy of Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Trial ID: NCT07872709
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myeloid Malignancies
Trial ID: NCT05565105
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery
Trial ID: NCT07587749
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
NeoTILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
Trial ID: NCT07743190
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Trial ID: NCT07153055
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
An Open-Label, Phase II Study Evaluating the Feasibility, Safety, and Efficacy of Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Trial ID: NCT07872709
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 14, 2026
Conditions (Registry-Reported):
Skin Substitutes Versus Secondary Intention Healing After Mohs Micrographic Surgery
Trial ID: NCT07587749
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myeloid Malignancies
Trial ID: NCT05565105
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Trial ID: NCT07521657
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder Cancer
Trial ID: NCT07793578
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 5, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Phase 1 Trial of Trastuzumab Deruxtecan With Stereotactic Radiosurgery (SRS) in Participants With Brain Metastases From HER-2 Positive Breast Cancer
Trial ID: NCT07454668
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 1, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
SEMAGLUTIDE, WEIGHT LOSS, AND INTRAUTERINE THERAPY FOR FERTILITY-SPARING AND CONSERVATIVE TREATMENT FOR ENDOMETRIAL ATYPICAL HYPERPLASIA AND EARLY-STAGE, GRADE 1 ENDOMETRIOID ENDOMETRIAL CANCER
Trial ID: NCT07820358
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 15, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
Phase 1b Study of Monzosertib In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome
Trial ID: NCT07780565
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Trial ID: NCT07078838
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 28, 2026
Conditions (Registry-Reported):
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Trial ID: NCT05728879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 1, 2026
Conditions (Registry-Reported):
A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
Trial ID: NCT04373785
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 21, 2025
Conditions (Registry-Reported):
A Phase 1/2a Clinical Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Novel mRNA-LNP PMC2129G12-Based Immunotherapy in Patients With Advanced Malignant Solid Tumors
Trial ID: NCT07587879
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 14, 2026
Conditions (Registry-Reported):
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Trial ID: NCT07450183
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Trial ID: NCT07765836
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1 Dose-escalation Study of Topical Duvelisib in Patients With Early-stage Mycosis Fungoides
Trial ID: NCT07714187
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)
Trial ID: NCT07037004
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Trial ID: NCT07819396
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 14, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Trial ID: NCT07874828
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Trial ID: NCT07874828
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Trial ID: NCT07874828
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)
Trial ID: NCT07638982
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 16, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Trial ID: NCT07874828
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 15, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma
Trial ID: NCT07862530
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 7, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase II Study of Induction/Window of Opportunity Toripalimab Followed by Definitive Chemoradiotherapy (CRT) and Adjuvant Toripalimab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Trial ID: NCT07836049
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 23, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
Phase 1 Dose Escalation And Expansion Study Of Intralesional TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
Trial ID: NCT07631013
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 11, 2026
Conditions (Registry-Reported):
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial ID: NCT07848295
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 30, 2026
Conditions (Registry-Reported):
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Trial ID: NCT07261241
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 21, 2026
Conditions (Registry-Reported):
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Trial ID: NCT05038098
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: August 14, 2026
Conditions (Registry-Reported):
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Trial ID: NCT07674823
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 11, 2026
Conditions (Registry-Reported):
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Trial ID: NCT07674810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 30, 2026
Conditions (Registry-Reported):
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial ID: NCT05521997
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 3, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Trial ID: NCT07164469
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 15, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Trial ID: NCT07595874
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 1, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Single-Center, Prospective Pilot Trial of Circadian-Optimized Light Therapy (COLT) in Patients Undergoing Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Trial ID: NCT07628894
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 5, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT07578077
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 11, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
Pilot Study: Evaluation of Novel Data-Driven Outcomes Via Response-Guided Systems Medicine in Hormone Receptor-Positive Advanced Breast Cancer (ENDORSE)
Trial ID: NCT07590583
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 15, 2026
Conditions (Registry-Reported):
A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial ID: NCT07582159
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 12, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Trial ID: NCT07634601
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 9, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma
Trial ID: NCT07583810
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: September 29, 2026
Conditions (Registry-Reported):
A Phase 1 Clinical Trial of 64Cu-DOTA A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) Positron Emission Tomography in Patients With Metastatic PSCA-Expressing Pancreatic Cancer
Trial ID: NCT07608627
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 27, 2026
Conditions (Registry-Reported):
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Trial ID: NCT07682454
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Trial ID: NCT07682454
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Trial ID: NCT07682454
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Trial ID: NCT07682454
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: October 13, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
Trial ID: NCT07354100
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Trial ID: NCT07583303
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: May 13, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
Trial ID: NCT07603856
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: June 16, 2026
Conditions (Registry-Reported):
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Trial ID: NCT07714421
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Trial ID: NCT07714421
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Trial ID: NCT07714421
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Trial ID: NCT07714421
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
A Phase I Study of Single Agent Epcoritamab Followed by Epcoritamab Plus Pola-R-Mini-CHP for Elderly/Unfit Patients With Previously Untreated DLBCL
Trial ID: NCT07714421
Geography: U.S.
Registry Source: ClinicalTrials.gov API v2
Last Updated: July 20, 2026
Conditions (Registry-Reported):
Trial Categorization: Trials are programmatically categorized into US vs International using sponsor and study location metadata. If sponsor/locations change in the registry, categorization may update at the next refresh.
Note on Trial IDs: Each listed trial carries its ClinicalTrials.gov NCT identifier. Use the card's registry link to verify its current record.
Understanding Clinical Trials in Oncology Research
Educational overview of how experimental oncology research is studied and evaluated across cancer types and trial phases
✓ US & International trials • Public registry records • Evidence context overview
